Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

If you need an accessible version of this item please contact JSTOR User Support

Ciprofloxacin Treatment of Drug-Resistant Falciparum Malaria

George Watt, G. Dennis Shanks, Michael D. Edstein, Katchrinnee Pavanand, H. Kyle Webster and Suwit Wechgritaya
The Journal of Infectious Diseases
Vol. 164, No. 3 (Sep., 1991), pp. 602-604
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/30111713
Page Count: 3
  • Download ($42.00)
  • Cite this Item
If you need an accessible version of this item please contact JSTOR User Support
Ciprofloxacin Treatment of Drug-Resistant Falciparum Malaria
Preview not available

Abstract

A randomized, open study of high-dose ciprofloxacin (750 mg every 12 h) in uncomplicated falciparum malaria was conducted in Thailand. No patient completed the planned 1-week treatment course. Because of rising parasitemia (threefold higher at 36 h than on admission) and deterioration of clinical status, three individuals required quinine treatment 36 h after commencing ciprofloxacin; a fourth was given quinine at 54 h. The study was terminated early for safety reasons after only four ciprofloxacin and four control patients had been enrolled. Ciprofloxacin was well absorbed and efficiently entered erythrocytes; median plasma and red cell concentrations 90 min after the first dose were 4.0 (range, 3.7-6.8) and 5.1 (3.8-6.0) µg/ml, respectively. However, 5O% inhibition of parasite growth in vitro required 6.6 µg/ml (5.6-9.6). Ciprofloxacin should not be used alone to treat chloroquine-resistant falciparum malaria.

Page Thumbnails

  • Thumbnail: Page 
602
    602
  • Thumbnail: Page 
603
    603
  • Thumbnail: Page 
604
    604